As the global economy mends, the 2021 growth of T Cell Antigen Gp39 will have significant change from previous year. According to our (LP Information) latest study, the global T Cell Antigen Gp39 market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global T Cell Antigen Gp39 market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States T Cell Antigen Gp39 market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global T Cell Antigen Gp39 market, reaching US$ million by the year 2028. As for the Europe T Cell Antigen Gp39 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main T Cell Antigen Gp39 players cover Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, and ImmuNext, Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of T Cell Antigen Gp39 market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
ECI-006
Hepatitis B Vaccine
INX-021
ISF-35
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Graft Versus Host Disease
Breast Cancer
Bladder Cancer
Panceratic Cancer
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Biogen, Inc.
Bristol-Myers Squibb Company
eTheRNA Immunotherapies NV
ImmuNext, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Targovax AS
XL-protein GmbH